Contact us
Young GI
Patients
Industry
Press
My Connect
Create myUEG account
About
To landing page
Who we are
Boards, Committees & Groups
Governance
Headquarters Management
History
What we do
Strategic Drivers
Year in Review
Our Members
Specialist Member Societies
National Member Societies
myUEG Community
myUEG Associates
My Connect
Women in GI
Young GIs
Researchers
Event Calendar
Week
To landing page
Programme
Postgraduate Teaching
Industry
Supporters
CME Accreditation
UEG Week on-demand
Future UEG Weeks
Education
To landing page
Online Education
Online Courses
Webinars
Career Development
Face-to-face Education
Summer School
Masterclass
Clinical Visiting Fellowships
Education Resources
Mistakes in...
UEG Talks Podcast
Image Hub
CME in Europe
Event Endorsement
Supporters
Research
To landing page
Support
Horizon Europe Support
Start-up Grant
Research Prize
Research Fellowship
Research Webinars
Research Projects
HoloSurge
Position Papers
White Book 2
Main Results
Full Reports
Materials and Presentations
Quality of Care
To landing page
Search Guidelines
Standards & Guidelines Repository
Non-English Guidelines
GI Guidelines App
Develop & Implement
How to develop guidelines
Guideline Endorsement
Guideline Webinars
Projects
Quality of Care Initiatives
Quality Standards
Public Affairs
To landing page
Advocacy
Core Positions
Stakeholder Collaboration
White Book 2
Position Papers
MEP Digestive Health Group
Our Supporters
#EUNewsline →
EU Elections 2024
Publications
To landing page
Publications
Congress Publications
Research Publications
Public Affairs Publications
Education Publications
UEG Publications
UEG Journal →
UEG Journal Podcast
White Book 2
Opportunities
To landing page
Congress Opportunities
Top Abstract Prizes
National Scholar Award
Travel Grants
International Scholarship Awards
Research Funding
Research Prize
Research Fellowship
Horizon Europe Support
Start-up Grant
Activities Funding
Recognition of Achievements
Lifetime Achievement Award
Journal Best Paper Award
Activities Endorsement
Professional Advancement
Rising Star Awards
Clinical Visiting Fellowships
Open Positions
Talent Pool
Library
To landing page
Congress Resources
UEG Week on-demand
Abstracts
Posters
Guideline Resources
Education Resources
Image Hub
Webinars
Mistakes in... articles
Contact us
Young GI
Patients
Industry
Press
Author
Laurent Peyrin-Biroulet
TREAT-TO-TARGET MAINTENANCE EFFICACY AND PHARMACOKINETICS OF USTEKINUMAB DOSING REGIMEN UP TO WEEK 48 IN THE STARDUST TRIAL
Laurent Peyrin-Biroulet
et al.
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY
Laurent Peyrin-Biroulet
et al.
COMPARATIVE EFFECTIVENESS OF USTEKINUMAB AND ADALIMUMAB IN THE PREVENTION OF POST-OPERATIVE RECURRENCE IN CROHN’S DISEASE
Laurent Peyrin-Biroulet
et al.
TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
Laurent Peyrin-Biroulet
et al.
AN EXPERT CONSENSUS TO STANDARDIZE THE ASSESSMENT OF HISTOLOGIC DISEASE ACTIVITY IN CROHN'S DISEASE CLINICAL TRIALS
Laurent Peyrin-Biroulet
et al.
EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Laurent Peyrin-Biroulet
et al.
DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH
Laurent Peyrin-Biroulet
et al.
INFLIXIMAB PLUS AZATHIOPRINE AND QUICK STEROIDS DISCONTINUATION VERSUS AZATHIOPRINE PLUS STEROIDS IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS RESPONDING TO INTRAVENOUS STEROIDS: A PARALLEL, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
Laurent Peyrin-Biroulet
et al.
EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY
Laurent Peyrin-Biroulet
et al.
THIRD-LINE THERAPY IN REFRACTORY ULCERATIVE COLITIS: A COMPARISON BETWEEN TOFACITINIB AND USTEKINUMAB
Laurent Peyrin-Biroulet
et al.
CLINICAL PROOF OF PRINCIPLE AND FAVORABLE TOLERABILITY PROFILE SHOWN WITH ORALLY DOSED MORF-057 AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE UC: PHASE 2A EMERALD-1 STUDY RESULTS
Laurent Peyrin-Biroulet
et al.
PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY
Laurent Peyrin-Biroulet
et al.
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
Laurent Peyrin-Biroulet
et al.
IMPACT OF BIOLOGICS ON THE RISK OF EARLY POSTOPERATIVE COMPLICATIONS IN CROHN'S DISEASE: A FRENCH NATIONWIDE STUDY
Laurent Peyrin-Biroulet
et al.
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
Laurent Peyrin-Biroulet
et al.
Item 101 - 115 / 115
1
2
3
4
5
6
Chat with us
, powered by
LiveChat